Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]
The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]
For too long, if you ask me, the Japan pharmaceutical market opportunity has been treated as […]
This article is a run-through of organoids and organs-on-chips in drug discovery! Drug discovery has a […]
Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]
Let’s be brutally honest: the traditional event experience is fundamentally broken. It is a relic of […]
Radioligand therapy is now a board-level topic in Japan, not because the science is new, but […]
H&M invented a new kind of shrinkflation, taking the size of male underwear down. L suddenly […]